Compare IRM & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRM | ILMN |
|---|---|---|
| Founded | 1951 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0B | 37.0B |
| IPO Year | 1997 | 2000 |
| Metric | IRM | ILMN |
|---|---|---|
| Price | $114.60 | $271.18 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 21 |
| Target Price | $144.00 | ★ $233.55 |
| AVG Volume (30 Days) | 1.3M | ★ 3.7M |
| Earning Date | 11-04-2026 | 10-29-2026 |
| Dividend Yield | ★ 3.00% | N/A |
| EPS Growth | N/A | ★ 170.87 |
| EPS | 0.82 | ★ 2.22 |
| Revenue | ★ $4,491,531,000.00 | $4,343,000,000.00 |
| Revenue This Year | $16.38 | $6.48 |
| Revenue Next Year | $8.96 | $6.46 |
| P/E Ratio | $140.06 | ★ $124.54 |
| Revenue Growth | ★ 8.30 | N/A |
| 52 Week Low | $77.77 | $90.10 |
| 52 Week High | $134.68 | $309.35 |
| Indicator | IRM | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 48.72 | 59.30 |
| Support Level | $109.72 | $116.43 |
| Resistance Level | $117.63 | $309.35 |
| Average True Range (ATR) | 2.60 | 14.89 |
| MACD | 0.51 | -1.41 |
| Stochastic Oscillator | 63.43 | 35.77 |
Iron Mountain Inc is an information management services provider organized and operated as a real estate investment trust. The company offers solutions to its clients to address their information management, digital transformation, information security, data center, and asset lifecycle management (ALM) needs. Its customers come from various industries, including commercial, legal, financial, healthcare, technology, etc. The company has two reportable segments: Global Records and Information Management (Global RIM) and Global Data Center. Maximum revenue is generated from the Global RIM segment, which offers data and records management, secure shredding, consumer storage, and other related services. Geographically, the company generates maximum revenue from the United States.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.